U.S. markets close in 3 hours 45 minutes

Oppenheimer Sticks to Their Hold Rating for Nektar Therapeutics


Oppenheimer analyst Jay Olson maintained a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Sunday, setting a price target of $25, which is approximately 13.53% above the present share price of $22.02.

Olson expects Nektar Therapeutics to post earnings per share (EPS) of -$0.78 for the second quarter of 2020.

The current consensus among 11 TipRanks analysts is for a Moderate Buy rating of shares in Nektar Therapeutics, with an average price target of $26.64.
The analysts price targets range from a high of $35 to a low of $18.

In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $50.57 million and a net profit of -$88.44 million. The company's market cap is $3.92 billion.

According to TipRanks.com, Oppenheimer analyst Jay Olson has 0 stars on 0-5 stars ranking scale with an average return of -7.8% and a 39.0% success rate.

Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.